Principal Investigator
Lisa M Wintner
Medical University of Innsbruck
Austria
Project Coordination
Franziska Gross
Medical University of Innsbruck
Austria
Collaborators
Mieke van Hemelijck, King’s College London, UK
Elisabeth Beisland, Høgskulen på Vestlandet, Bergen, Norway
Christian Beisland, University of Bergen, Norway
Manjunath Nookala Krishnamurthy, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Hospital, Mumbai, India
Project Summary
In 2019, the EORTC Quality of Life Group initiated the development of an disease-specific quality-of-life measure for renal cell carcinoma (RCC), the most common form of kidney cancer. This initiative was driven by the fact that the EORTC conducts clinical trials involving RCC patients, yet no EORTC RCC-specific quality-of-life instrument is currently available. Although relatively rare, RCC is often fatal because early stages are typically asymptomatic and diagnosis frequently occurs at an advanced stage.
This development effort has resulted in the preliminary 38-item QLQ-RCC38 module. The current project represents a Phase III study aimed at refining the module by evaluating its relevance across different disease stages and treatment modalities, followed by necessary adaptations. In addition, the study will collect data to conduct preliminary psychometric analyses.
Project Status
ongoing Phase IIIa: Structured interviews with patients for module refinement
planned Phase IIIb: Patients will complete the adapted QLQ-RCC38 and a debriefing questionnaire
Dissemination
